Cargando…

Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study

In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Angelo, Salvatore, Tirri, Enrico, Giardino, Angela Maria, Mattucci-Cerinic, Marco, Dagna, Lorenzo, Santo, Leonardo, Ciccia, Francesco, Frediani, Bruno, Govoni, Marcello, Bobbio Pallavicini, Francesca, Grembiale, Rosa Daniela, Delle Sedie, Andrea, Mulè, Rita, Cantatore, Francesco Paolo, Foti, Rosario, Gremese, Elisa, Conigliaro, Paola, Salaffi, Fausto, Viapiana, Ombretta, Cauli, Alberto, Giacomelli, Roberto, Arcarese, Luisa, Guggino, Giuliana, Russo, Romualdo, Puenpatom, Amy, Capocotta, Domenico, Nacci, Francesca, Anelli, Maria Grazia, Picerno, Valentina, Binetti, Corrado, Iannone, Florenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322086/
https://www.ncbi.nlm.nih.gov/pubmed/35887946
http://dx.doi.org/10.3390/jcm11144178
_version_ 1784756210651627520
author D’Angelo, Salvatore
Tirri, Enrico
Giardino, Angela Maria
Mattucci-Cerinic, Marco
Dagna, Lorenzo
Santo, Leonardo
Ciccia, Francesco
Frediani, Bruno
Govoni, Marcello
Bobbio Pallavicini, Francesca
Grembiale, Rosa Daniela
Delle Sedie, Andrea
Mulè, Rita
Cantatore, Francesco Paolo
Foti, Rosario
Gremese, Elisa
Conigliaro, Paola
Salaffi, Fausto
Viapiana, Ombretta
Cauli, Alberto
Giacomelli, Roberto
Arcarese, Luisa
Guggino, Giuliana
Russo, Romualdo
Puenpatom, Amy
Capocotta, Domenico
Nacci, Francesca
Anelli, Maria Grazia
Picerno, Valentina
Binetti, Corrado
Iannone, Florenzo
author_facet D’Angelo, Salvatore
Tirri, Enrico
Giardino, Angela Maria
Mattucci-Cerinic, Marco
Dagna, Lorenzo
Santo, Leonardo
Ciccia, Francesco
Frediani, Bruno
Govoni, Marcello
Bobbio Pallavicini, Francesca
Grembiale, Rosa Daniela
Delle Sedie, Andrea
Mulè, Rita
Cantatore, Francesco Paolo
Foti, Rosario
Gremese, Elisa
Conigliaro, Paola
Salaffi, Fausto
Viapiana, Ombretta
Cauli, Alberto
Giacomelli, Roberto
Arcarese, Luisa
Guggino, Giuliana
Russo, Romualdo
Puenpatom, Amy
Capocotta, Domenico
Nacci, Francesca
Anelli, Maria Grazia
Picerno, Valentina
Binetti, Corrado
Iannone, Florenzo
author_sort D’Angelo, Salvatore
collection PubMed
description In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were also assessed. A total of 194 patients aged 53.2 ± 12 years started GLM as a second anti-TNF drug: 39 (20.1%) with RA, 91 (46.9%) with PsA and 64 (32.9%) with axSpA. After 6 months of GLM treatment, 68% of RA patients achieved low disease activity (LDA; DAS28-CRP ≤ 3.2), 31.9% of PsA patients achieved minimal disease activity and 32.5% of axSpA patients achieved LDA (ASDAS-CRP < 2.1). Good/moderate EULAR response was achieved in 61.9% and 73.8% of patients with RA and PsA, respectively, and 16% of axSpA patients achieved a 50% improvement in BASDAI. Across all indications, improvements in disease activity measures and EQ-5D-5L domains were observed over 6 months. The main reasons for GLM interruption were lack/loss of efficacy (7.2%) or adverse events (2%). This study confirms the effectiveness of GLM as a second-line anti-TNF for the treatment of RA, PsA and axSpA in a real-world setting in Italy.
format Online
Article
Text
id pubmed-9322086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93220862022-07-27 Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study D’Angelo, Salvatore Tirri, Enrico Giardino, Angela Maria Mattucci-Cerinic, Marco Dagna, Lorenzo Santo, Leonardo Ciccia, Francesco Frediani, Bruno Govoni, Marcello Bobbio Pallavicini, Francesca Grembiale, Rosa Daniela Delle Sedie, Andrea Mulè, Rita Cantatore, Francesco Paolo Foti, Rosario Gremese, Elisa Conigliaro, Paola Salaffi, Fausto Viapiana, Ombretta Cauli, Alberto Giacomelli, Roberto Arcarese, Luisa Guggino, Giuliana Russo, Romualdo Puenpatom, Amy Capocotta, Domenico Nacci, Francesca Anelli, Maria Grazia Picerno, Valentina Binetti, Corrado Iannone, Florenzo J Clin Med Article In this prospective observational study, data were collected from 34 rheumatology clinics in Italy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who started golimumab (GLM) as a second anti-TNFα drug. The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were also assessed. A total of 194 patients aged 53.2 ± 12 years started GLM as a second anti-TNF drug: 39 (20.1%) with RA, 91 (46.9%) with PsA and 64 (32.9%) with axSpA. After 6 months of GLM treatment, 68% of RA patients achieved low disease activity (LDA; DAS28-CRP ≤ 3.2), 31.9% of PsA patients achieved minimal disease activity and 32.5% of axSpA patients achieved LDA (ASDAS-CRP < 2.1). Good/moderate EULAR response was achieved in 61.9% and 73.8% of patients with RA and PsA, respectively, and 16% of axSpA patients achieved a 50% improvement in BASDAI. Across all indications, improvements in disease activity measures and EQ-5D-5L domains were observed over 6 months. The main reasons for GLM interruption were lack/loss of efficacy (7.2%) or adverse events (2%). This study confirms the effectiveness of GLM as a second-line anti-TNF for the treatment of RA, PsA and axSpA in a real-world setting in Italy. MDPI 2022-07-19 /pmc/articles/PMC9322086/ /pubmed/35887946 http://dx.doi.org/10.3390/jcm11144178 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
D’Angelo, Salvatore
Tirri, Enrico
Giardino, Angela Maria
Mattucci-Cerinic, Marco
Dagna, Lorenzo
Santo, Leonardo
Ciccia, Francesco
Frediani, Bruno
Govoni, Marcello
Bobbio Pallavicini, Francesca
Grembiale, Rosa Daniela
Delle Sedie, Andrea
Mulè, Rita
Cantatore, Francesco Paolo
Foti, Rosario
Gremese, Elisa
Conigliaro, Paola
Salaffi, Fausto
Viapiana, Ombretta
Cauli, Alberto
Giacomelli, Roberto
Arcarese, Luisa
Guggino, Giuliana
Russo, Romualdo
Puenpatom, Amy
Capocotta, Domenico
Nacci, Francesca
Anelli, Maria Grazia
Picerno, Valentina
Binetti, Corrado
Iannone, Florenzo
Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
title Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
title_full Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
title_fullStr Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
title_full_unstemmed Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
title_short Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
title_sort effectiveness of golimumab as second anti-tnfα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in italy: go-beyond, a prospective real-world observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322086/
https://www.ncbi.nlm.nih.gov/pubmed/35887946
http://dx.doi.org/10.3390/jcm11144178
work_keys_str_mv AT dangelosalvatore effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT tirrienrico effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT giardinoangelamaria effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT mattuccicerinicmarco effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT dagnalorenzo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT santoleonardo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT cicciafrancesco effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT fredianibruno effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT govonimarcello effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT bobbiopallavicinifrancesca effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT grembialerosadaniela effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT dellesedieandrea effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT mulerita effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT cantatorefrancescopaolo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT fotirosario effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT gremeseelisa effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT conigliaropaola effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT salaffifausto effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT viapianaombretta effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT caulialberto effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT giacomelliroberto effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT arcareseluisa effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT gugginogiuliana effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT russoromualdo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT puenpatomamy effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT capocottadomenico effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT naccifrancesca effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT anellimariagrazia effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT picernovalentina effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT binetticorrado effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy
AT iannoneflorenzo effectivenessofgolimumabassecondantitnfadruginpatientswithrheumatoidarthritispsoriaticarthritisandaxialspondyloarthritisinitalygobeyondaprospectiverealworldobservationalstudy